The firm will provide manufacturing and regulatory support as UW prepares an IND submission for its GD2 CAR T-cell therapy.
The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.
A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.
The driving force behind the lab was a desire to control biomarker discovery, streamline regulatory approvals for CDx, and develop drugs more cheaply and quickly.